We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
76
DELISTED
Centessa Pharmaceuticals
CNTA
$5.49M 0.03%
1,127,273
– –
NKTX icon
77
Nkarta
NKTX
$152M
$4.93M 0.03%
+400,000
New +$5.25M
VERA icon
78
Vera Therapeutics
VERA
$2.33B
$4.54M 0.03%
333,333
– –
RVMD icon
79
Revolution Medicines
RVMD
$38.5B
$4.33M 0.02%
222,222
– –
EWTX icon
80
Edgewise Therapeutics
EWTX
$4.28B
$3.98M 0.02%
500,000
– –
NGNE icon
81
Neurogene
NGNE
$672M
$3.94M 0.02%
191,087
– –
HOOK
82
DELISTED
HOOKIPA Pharma
HOOK
$3.91M 0.02%
240,048
– –
NTRA icon
83
Natera
NTRA
$36.4B
$3.54M 0.02%
+100,000
New +$3.7M
TNGX icon
84
Tango Therapeutics
TNGX
$4.21B
$3.4M 0.02%
750,000
– –
LONA
85
LeonaBio Inc
LONA
$66.1M
$3.17M 0.02%
104,083
+23,446
+29% +$2.15M
ITOS
86
DELISTED
iTeos Therapeutics
ITOS
$3.1M 0.02%
150,346
– –
EVFM
87
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$2.92M 0.02%
+2,583,616
New +$4.26M
MGNX icon
88
MacroGenics
MGNX
$233M
$2.63M 0.01%
892,579
+450,000
+102% +$2.37M
ALGS icon
89
Aligos Therapeutics
ALGS
$26.3M
$2.51M 0.01%
83,056
– –
ALEC icon
90
Alector
ALEC
$169M
$2.43M 0.01%
239,228
– –
BCAB icon
91
BioAtla
BCAB
$5.34M
$2.35M 0.01%
16,500
– –
ALLK
92
DELISTED
Allakos
ALLK
$2.2M 0.01%
703,050
– –
TCRR
93
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.18M 0.01%
753,064
– –
SNDX icon
94
Syndax Pharmaceuticals
SNDX
$1.7B
$2.13M 0.01%
110,729
– –
SYRE icon
95
Spyre Therapeutics
SYRE
$8.5B
$1.72M 0.01%
136,404
– –
EPZM
96
DELISTED
Epizyme, Inc
EPZM
$1.47M 0.01%
1,000,000
– –
AKRO
97
DELISTED
Akero Therapeutics
AKRO
$1.12M 0.01%
118,378
– –
ATYR
98
aTyr Pharma
ATYR
$47.4M
$1.06M 0.01%
374,395
-250,605
-40% -$906K
GTH
99
DELISTED
Genetron Holdings Limited ADS
GTH
$774K ﹤0.01%
151,769
– –
NGM
100
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$709K ﹤0.01%
55,294
-236,507
-81% -$3.28M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Baker Bros. Advisors held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Baker Bros. Advisors added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Baker Bros. Advisors's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Baker Bros. Advisors fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q2 2022.
  • Baker Bros. Advisors's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.